CAN (Canstatin)
Canstatin, released NC1 domain of type IV collagen a2 chain, enabling non-invasive monitoring of angiogenesis and extracellular matrix remodeling in pathological conditions such as cancer and fibrotic diseases.
Key features and values
- Quantifies canstatin fragments associated with extracellular matrix remodeling.
- Reflects changes in angiogenesis and tissue remodeling processes.
- Provides a non-invasive measure of pathological extracellular matrix dynamics.
- Supports monitoring of disease progression and response to therapies targeting extracellular matrix remodeling.
- Applicable in research on diseases characterized by aberrant angiogenesis and extracellular matrix turnover, such as cancer and fibrosis.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The CAN (Canstatin) biomarker assay measures specific fragments of canstatin, a bioactive peptide derived from type IV collagen, serving as an indicator of angiogenesis and extracellular matrix remodeling. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in conditions such as cancer and fibrotic diseases. By quantifying canstatin fragments associated with extracellular matrix remodeling, the CAN assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of extracellular matrix turnover.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
